During the last session, Predictive Oncology Inc (NASDAQ:POAI)’s traded shares were 1.0 million, with the beta value of the company hitting 1.12. At the end of the trading day, the stock’s price was $1.53, reflecting an intraday loss of -4.38% or -$0.07. The 52-week high for the POAI share is $3.06, that puts it down -100.0 from that peak though still a striking 64.05% gain since the share price plummeted to a 52-week low of $0.55. The company’s market capitalization is $11.03M, and the average intraday trading volume over the past 10 days was 15.84 million shares, and the average trade volume was 4.77 million shares over the past three months.

Predictive Oncology Inc (POAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. POAI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.

Predictive Oncology Inc (NASDAQ:POAI) trade information

Predictive Oncology Inc (POAI) registered a -4.38% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -4.38% in intraday trading to $1.53, hitting a weekly high. The stock’s 5-day price performance is 39.09%, and it has moved by 7.75% in 30 days. Based on these gigs, the overall price performance for the year is -41.38%. The short interest in Predictive Oncology Inc (NASDAQ:POAI) is 0.4 million shares and it means that shorts have 0.99 day(s) to cover.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 350k as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 1.5M by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 53.33%. While earnings are projected to return 40.23% in 2025.

POAI Dividends

Predictive Oncology Inc is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Predictive Oncology Inc (NASDAQ:POAI)’s Major holders

Predictive Oncology Inc insiders own 1.55% of total outstanding shares while institutional holders control 3.34%, with the float percentage being 3.39%. ADVISORNET FINANCIAL, INC is the largest shareholder of the company, while 18.0 institutions own stock in it. As of 2024-06-30, the company held over 95.0 shares (or 0.0023% of all shares), a total value of $99.0 in shares.